Northwire Canada EditionMonday, July 27, 2026
Northwire
B 0.150 +0.0% IFOS 2.28 −2.6% IMM 0.060 +0.0% ROCK 3.38 −1.7% NVX 0.250 −7.4% HAR 0.050 +0.0% YGT 0.175 +0.0% GEN 0.070 −nan% CRB 0.040 +14.3% MSA 7.07 +2.2% AEM 204.81 +0.7% OPW 0.105 +5.0% GRL 0.275 −1.8% AIS 0.150 +0.0% CUU 0.580 −1.7% SOMA 0.720 +5.9% B 0.150 +0.0% IFOS 2.28 −2.6% IMM 0.060 +0.0% ROCK 3.38 −1.7% NVX 0.250 −7.4% HAR 0.050 +0.0% YGT 0.175 +0.0% GEN 0.070 −nan% CRB 0.040 +14.3% MSA 7.07 +2.2% AEM 204.81 +0.7% OPW 0.105 +5.0% GRL 0.275 −1.8% AIS 0.150 +0.0% CUU 0.580 −1.7% SOMA 0.720 +5.9%
M&A / Property

AI/ML Innovations Inc. Announces Grant of U.S. Patent Protecting Core ECG Signal-Processing Architecture

AIML · Price

Executive Summary

  • The United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent No. 12,465,266 covering AIML’s core machine‑learning architecture for ECG signal denoising and wave‑property identification.
  • The allowed claims protect the proprietary approach used in the company’s MaxYield™ and CardioYield™ products, reinforcing its competitive advantage as it moves toward commercialization and regulatory approvals.
  • Company leadership highlighted the allowance as a significant milestone that strengthens AIML’s IP portfolio and supports ongoing product deployment globally.

Key Details

  • Patent Information: U.S. Patent No. 12,465,266 (Notice of Allowance) for the core ML architecture behind Neural Cloud’s ECG wave‑property identification engine.
  • Scope of Protection: Broad claims covering denoising of ECG signals, beat‑level morphology identification, and association of patterns with clinically meaningful cardiac rhythm conditions.
  • Strategic Impact: Enhances AIML’s intellectual property position, supporting commercialization, regulatory pathways, and clinical validation across cardiology, remote monitoring, telehealth, and research applications.
  • Portfolio Context: First allowance among several pending patent applications in AIML’s IP portfolio; additional filings are underway.
  • Product Linkage: Underpins downstream products MaxYield™ and CardioYield™, enabling high‑fidelity, clinically interpretable cardiac insights.
  • Leadership Quotes:
  • Esmat Naikyar, President of Neural Cloud – “This patent represents an exciting milestone for our platform…”.
  • Paul Duffy, Executive Chairman & CEO – “The allowance validates both our technical innovation and our long‑term vision…”.

Notable Quotes

  • “The core signal‑processing and wave‑morphology identification engine is what enables our downstream products—including MaxYield™ and CardioYield™—to deliver high‑fidelity, clinically interpretable cardiac insights.” – Esmat Naikyar
  • “It provides strong protection around the architecture we have developed, positioning AIML with a meaningful competitive advantage as we advance commercialization.” – Paul Duffy
Read the original news release →

More from AI-ML Innovations Inc.